Group 1: Company Overview - Alumis (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases [3][4]. - The company recently closed at $16.23, marking a significant increase of 95.31% in a single trading session, with trading volume reaching 64.1 million shares, which is approximately 3,077% above its three-month average [1]. Group 2: Recent Developments - The surge in Alumis' stock price followed the announcement of positive Phase 3 psoriasis data for its drug envudeucitinib, which met both primary and secondary endpoints with strong statistical significance in patients with moderate-to-severe plaque psoriasis [3][4]. - Alumis plans to capitalize on its stock price increase by initiating a $175 million offering of its common stock to support the commercialization of envudeucitinib and its drug pipeline [4]. Group 3: Market Context - The broader market saw the S&P 500 rise by 0.62% and the Nasdaq Composite gain 0.65%, indicating a generally positive sentiment in the market, although biotechnology stocks like Summit Therapeutics and Insmed experienced mixed movements [2]. - The reaction of small biotech stocks to trial news can be binary, leading to significant price fluctuations, as evidenced by Alumis' nearly doubling in value following the trial results [4].

Core Viewpoint - Alumis Inc (NASDAQ:ALMS) is experiencing significant stock price growth following successful trial results for its psoriasis drug, envudeucitinib, positioning the company as a strong competitor in the biopharmaceutical market for autoimmune diseases [2][5]. Group 1: Stock Performance - The stock price of ALMS surged 107.9% to $17.28 after the successful phase three trial results of envudeucitinib [2][5]. - ALMS is on track to break a seven-day losing streak, with a year-over-year increase of approximately 108% [3]. - The stock price rose by $8.64, with a trading range from $16.40 to $22.30, marking its highest price over the past year [3]. Group 2: Market Capitalization and Trading Activity - The market capitalization of ALMS is approximately $1.77 billion [4][5]. - The trading volume for ALMS reached 49.14 million shares, with significant activity in the options market, including 3,492 calls and 5,948 puts traded, marking a volume 39 times higher than the stock's average daily options activity [4][5]. Group 3: Analyst Ratings - Wells Fargo maintained an "Overweight" rating for ALMS, raising the price target from $17 to $39 [1][5].

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of sh ...

Core Insights - Alumis Inc (NASDAQ:ALMS) shares surged by 107.9% to $17.28 after the company announced that its plaque psoriasis drug, envudeucitinib, successfully met all primary and secondary endpoints in both phase three trials [1] Group 1: Stock Performance - ALMS has reached record highs today, aiming to end a seven-day losing streak and potentially achieving its best day on record, with a year-over-year increase of approximately 100% [2] - The stock's options market is experiencing significant activity, with 3,492 calls and 5,948 puts traded, which is 39 times the average daily options volume [3] Group 2: Market Dynamics - The stock has been placed on the short sell restricted (SSR) list due to its volatility, with short interest accounting for 6.2% of the available float, equating to four days of potential buying power [4]

Alumis Inc. (NASDAQ:ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro.Alumis on Tuesday released topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib in patients with moderate-to-severe plaque psoriasis.Plaque psoriasis is the most common form of this chronic autoimmune skin condition, causing thick, red, inflamed patches (plaques) covered with silvery scales due to ra ...

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 100 points on Tuesday [1] - Microchip Technology Inc's shares rose significantly after the company revised its fiscal third-quarter revenue expectations upward [1] Group 2: Microchip Technology Inc - Microchip now anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, surpassing its previous guidance range of $1.109 billion to $1.149 billion [2] - The stock price of Microchip Technology increased by 8.1%, reaching $72.47 on Tuesday following the announcement [2] Group 3: Other Notable Stock Movements - Alumis Inc saw a remarkable 129% increase in its stock price to $19.04 after positive trial results for envudeucitinib [3] - Aeva Technologies Inc's stock rose by 31.5% to $17.21 due to its technology being selected for NVIDIA's autonomous vehicle platform [3] - Terrestrial Energy Inc's shares increased by 26.9% to $8.87 after securing an agreement with the U.S. Department of Energy [3] - Bright Minds Biosciences Inc gained 25% to $100.00 following successful Phase 2 trial results [3] - OneStream Inc's stock rose by 25.1% to $23.00 amid reports of a potential buyout [3] - Other companies such as SanDisk Corp, Beam Therapeutics Inc, and Albemarle Corp also recorded significant stock price increases [3]

在ONWARD1和ONWARD2中，Envudeucitinib以高统计学显著性达到了所有主要和次要终点。在这些试 验中，Envudeucitinib在第16周的银屑病面积和严重程度指数(PASI)75和静态医生整体评估(sPGA)0/1共 同主要终点上，相对于安慰剂表现出更优的皮肤清除效果(p<0.0001)。在ONWARD1和ONWARD2中平 均来看，74%的患者达到PASI75，59%的患者达到sPGA0/1，随着时间推移反应加深。此外，两个试验 之间共同主要终点的安慰剂校正响应率保持一致。 周二，Alumis(ALMS.US)开盘飙升超154%，创历史新高，报20.60美元。消息面上，该公司宣布了其 envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。Envudeucitinib是一种下一代高度 选择性的口服酪氨酸激酶2(TYK2)抑制剂，针对中度至重度斑块状银屑病患者。 ...

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite gaining over 50 points, while the Dow decreased by 0.03% to 48,962.01 and the S&P 500 rose by 0.14% to 6,911.52 [1] - Energy shares increased by 2.9%, while utilities stocks fell by 2.2% [1] Company Earnings - AngioDynamics, Inc. reported better-than-expected second-quarter results with an adjusted EPS of $0.00, surpassing market estimates of a loss of $0.10 per share. Sales reached $79.433 million, exceeding expectations of $76.300 million [2] Commodity Prices - Oil prices rose by 0.5% to $58.58, gold increased by 0.6% to $4,477.40, silver gained 2.4% to $78.505, and copper rose by 1.4% to $6.0565 [5] European Market Performance - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.3%, Spain's IBEX 35 Index rising 0.5%, London's FTSE 100 increasing by 1%, Germany's DAX gaining 0.4%, and France's CAC 40 slipping by 0.3% [6] Asian Market Performance - Asian markets closed mostly higher, with Japan's Nikkei 225 up 1.32%, Hong Kong's Hang Seng Index up 1.38%, China's Shanghai Composite surging 1.50%, while India's BSE Sensex fell by 0.44% [7] Notable Stock Movements - Alumis Inc. shares surged 148% to $20.54 following positive Phase 3 trial results for envudeucitinib in psoriasis [8] - Envirotech Vehicles, Inc. shares rose 73% to $0.6699 after announcing a merger transaction [8] - Cyclerion Therapeutics Inc. shares increased by 54% to $2.13 due to an expanded collaboration with Medsteer [8] - Instil Bio Inc. shares dropped 53% to $5.78 after discontinuing clinical development of AXN-2510 [8] - MOBIX LABS, INC. shares fell 45% to $0.18 following a $6.0 million stock offering [8] - BitVentures Ltd – ADR shares decreased by 23% to $11.40 [8] Economic Indicator - The Logistics Manager's Index declined for the second consecutive month to 54.2 in December, down from 55.7 in the previous two months [9]

在ONWARD1和ONWARD2中，Envudeucitinib以高统计学显著性达到了所有主要和次要终点。在这些试 验中，Envudeucitinib在第16周的银屑病面积和严重程度指数(PASI)75和静态医生整体评估(sPGA)0/1共 同主要终点上，相对于安慰剂表现出更优的皮肤清除效果(p < 0.0001)。在ONWARD1和ONWARD2中平 均来看，74%的患者达到PASI 75，59%的患者达到sPGA 0/1，随着时间推移反应加深。此外，两个试验 之间共同主要终点的安慰剂校正响应率保持一致。 智通财经APP获悉，周二，Alumis(ALMS.US)开盘飙升超154%，创历史新高，报20.60美元。消息面 上，该公司宣布了其envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。 Envudeucitinib是一种下一代高度选择性的口服酪氨酸激酶2(TYK2)抑制剂，针对中度至重度斑块状银屑 病患者。 ...

Alumis (NasdaqGS:ALMS) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsJohn Schroer - CFODerek Archila - Managing Director and Co-Head of Therapeutics ResearchMartin Babler - CEOJörn Drappa - CMOConference Call ParticipantsBrian Skorney - Senior Research AnalystYatin Suneja - Senior Managing Director and Biotechnology AnalystThomas Smith - Senior Research AnalystMitchell Kapoor - Director and Senior Biotechnology AnalystJeff Jones - Managing Director and Senior AnalystTerence Flynn - Equi ...